partager sur facebook

[News] Professor Stéphane Hatem appointed IHU-ICAN Director General


Center of scientific and medical excellence in the field of cardiometabolic diseases, the Institute IHU-ICAN welcomes Professor Stéphane Hatem as its new director general since January 2018. Professor Hatem is also a cardiac physiologist at the hospital group Pitié-Salpêtrière-Charles Foix and director of the Inserm research unit UMR_S1166.

The Institute of Cardiometabolism and Nutrition, ICAN, was created in 2011 with the objective of developing translational research on cardiometabolic diseases, a major public health problem. Heart and vessel diseases, obesity, diabetes, hepatic steatosis, etc., are often intricate and share pathophysiological mechanisms that require multidisciplinary approaches.

In close collaboration with its three founders—Paris Hospitals (AP-HP), the National Institute for Biomedical Research (INSERM) and the Sorbonne University—the IHU’s mission is to bring together multidisciplinary teams to battle this expected epidemic, improving early diagnosis, and developing personalized precision medicine.

Physiologist at the Cardiology Institute located within the Pitié Salpêtrière Hospital, Sorbonne University Professor, Director of the mixed Inserm research unit U1166 focused on cardiovascular, metabolic and nutrition diseases and now also Director General of the IHU-ICAN, Professor Hatem has been intimately involved with ICAN since it’s very inception. His research interests include cardiac electrophysiology, and more recently the relationships between adipose tissue and the myocardium in the development of cardiac arrhythmias. Professor Hatem is following in the footsteps of his predecessors, Professors Karine Clément and Florent Soubrier, to build an institute of excellence in the field of cardiometabolic research.

“Our IHU has achieved a real scientific and medical maturity. Five years ago, an institute on cardiometabolic diseases was a gamble. Today, it is self-evident.”

Professor Hatem emphasizes that the IHU must be open to all actors in the field, and continues:

“I recognize the significant work that has been achieved, and I am fully aware of what remains to be done.”

With access to state-of-the-art technological platforms, 400 doctors and expert researchers, and access to more than 40,000 patients who visit the Pitié-Salpêtrière Hospital’s cardiometabolic center each year, the IHU-ICAN is ready to take on the challenges of cardiometabolic diseases.